菲律宾 - 英文 - FDA (Food And Drug Administration)

novartis healthcare philippines, inc.; distributor: novartis healthcare philippines, inc. - pasireotide (as pamoate) - powder and solvent for suspension for injection (im) - 60mg

欧盟 - 英文 - EMA (European Medicines Agency)

recordati rare diseases - pasireotide - acromegaly; pituitary acth hypersecretion - pituitary and hypothalamic hormones and analogues - signifor is indicated for the treatment of adult patients with cushing’s disease for whom surgery is not an option or for whom surgery has failed.signifor is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.

新加坡 - 英文 - HSA (Health Sciences Authority)

pharm-d singapore private limited - pasireotide pamoate 27.42mg eqv pasireotide - injection, powder, for suspension - pasireotide pamoate 27.42mg eqv pasireotide 20mg

新加坡 - 英文 - HSA (Health Sciences Authority)

pharm-d singapore private limited - pasireotide pamoate 54.84mg eqv pasireotide - injection, powder, for suspension - pasireotide pamoate 54.84mg eqv pasireotide 40mg

新加坡 - 英文 - HSA (Health Sciences Authority)

pharm-d singapore private limited - pasireotide pamoate 82.26mg eqv pasireotide - injection, powder, for suspension - pasireotide pamoate 82.26mg eqv pasireotide 60mg

加拿大 - 英文 - Health Canada

recordati rare diseases canada inc - pasireotide (pasireotide diaspartate) - solution - 0.3mg - pasireotide (pasireotide diaspartate) 0.3mg - somatostatin agonists

加拿大 - 英文 - Health Canada

recordati rare diseases canada inc - pasireotide (pasireotide diaspartate) - solution - 0.6mg - pasireotide (pasireotide diaspartate) 0.6mg - somatostatin agonists

加拿大 - 英文 - Health Canada

recordati rare diseases canada inc - pasireotide (pasireotide diaspartate) - solution - 0.9mg - pasireotide (pasireotide diaspartate) 0.9mg - somatostatin agonists

美国 - 英文 - NLM (National Library of Medicine)

recordati rare diseases, inc. - pasireotide (unii: 98h1t17066) (pasireotide - unii:98h1t17066) - signifor lar is indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. signifor lar is indicated for the treatment of patients with cushing's disease for whom pituitary surgery is not an option or has not been curative. none. risk summary the limited data with signifor lar in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. in embryo-fetal development studies in rabbits, findings indicating a developmental delay were observed with subcutaneous administration of pasireotide during organogenesis at doses less than the exposure in humans at the highest recommended dose; maternal toxicity was not observed at this dose (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. data animal data in embryo-fetal development studies in rats given 1 mg/kg/day, 5 mg/kg/day, and 10 mg/kg/day subcutaneously throughout organogenesis, maternal toxicity was observed at all doses, including the lowest dose tested which had exposures 12 times higher than that at the maximum therapeutic dose based on area under the curve (auc) comparisons across species. an increased incidence of early/total resorptions and malrotated limbs was observed in rats at 10 mg/kg/day. at 10 mg/kg/day in rats, the maternal systemic exposure (auc) was 42179 ng*hr/ml, approximately 106 times the exposure in humans at the highest recommended dose of 60 mg signifor lar administered as an intramuscular injection once every 4 weeks. in embryo-fetal development studies in rabbits given 0.05 mg/kg/day, 1 mg/kg/day, and 5 mg/kg/day subcutaneously through organogenesis, maternal toxicity was observed at 1 mg/kg/day, at a maternal systemic exposure (auc) of 1906 ng*hr/ml, approximately 5 times higher than the maximum human therapeutic exposure. an increased incidence of unossified forepaw phalanx, indicative of a developmental retardation, was observed in rabbits at 0.05 mg/kg/day, with maternal systemic exposures less than the systemic exposure in humans at the highest recommended dose. in pre- and post-natal developmental studies in rats given subcutaneous doses of 2 mg/kg/day, 5 mg/kg/day, and 10 mg/kg/day during gestation through lactation and weaning, maternal toxicity was observed at all doses including the lowest dose (9 times higher than the maximum therapeutic dose based on surface area comparisons across species). retardation of physiological growth, attributed to gh inhibition was observed at 2 mg/kg/day during a pre- and post-natal study in rats. after weaning, body weight gains in the rat pups (f1 generation) exposed to pasireotide were comparable to controls, showing reversibility of this developmental delay. risk summary there is no information available on the presence of signifor lar in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. studies show that pasireotide administered subcutaneously passes into the milk of lactating rats; however, due to species-specific differences in lactation physiology, animal data may not reliably predict drug levels in human milk (see data) . the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for signifor lar, and any potential adverse effects on the breastfed child from signifor lar or from the underlying maternal condition. data available data in animals have shown excretion of pasireotide in milk. after a single 1 mg/kg [14 c]-pasireotide subcutaneous dose to lactating rats, the transfer of radioactivity into milk was observed. the overall milk:plasma (m/p) exposure ratio of total radioactivity was 0.28, based on auc0-∞ values. discuss the potential for unintended pregnancy with premenopausal women as the therapeutic benefits of a reduction in gh levels and normalization of igf-1 in acromegalic females treated with pasireotide may lead to improved fertility. similarly, the therapeutic benefits of a reduction or normalization of serum cortisol levels in female patients with cushing's disease treated with pasireotide may also lead to improved fertility. safety and effectiveness of signifor lar have not been established in pediatric patients. clinical studies of signifor lar did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. dose adjustment is not required in patients with mild impaired hepatic function (child-pugh a), but is required for patients with moderately impaired hepatic function (child-pugh b). the safety and efficacy of signifor lar have not been established in patients with severe hepatic impairment (child-pugh c). no dosage recommendation can be given for patients with severe hepatic impairment (child-pugh c) [see dosage and administration (2.5), clinical pharmacology (12.3)] . clinical studies of signifor lar in patients with renal impairment have not been conducted. on the basis of studies with pasireotide given subcutaneously, dosage adjustment is not needed in patients with renal impairment [see clinical pharmacology (12.3)] .

新加坡 - 英文 - HSA (Health Sciences Authority)

pharm-d singapore private limited - pasireotide diaspartate 0.37621mg eqv. pasireotide - injection, solution - 0.3mg - pasireotide diaspartate 0.37621mg eqv. pasireotide 0.3mg